Literature DB >> 26096556

Drug induced hypertension--An unappreciated cause of secondary hypertension.

Alon Grossman1, Franz H Messerli2, Ehud Grossman3.   

Abstract

Most patients with hypertension have essential hypertension or well-known forms of secondary hypertension, such as renal disease, renal artery stenosis, or common endocrine diseases (hyperaldosteronism or pheochromocytoma). Physicians are less aware of drug induced hypertension. A variety of therapeutic agents or chemical substances may increase blood pressure. When a patient with well controlled hypertension is presented with acute blood pressure elevation, use of drug or chemical substance which increases blood pressure should be suspected. Drug-induced blood pressure increases are usually minor and short-lived, although rare hypertensive emergencies associated with use of certain drugs have been reported. Careful evaluation of prescription and non-prescription medications is crucial in the evaluation of the hypertensive individual and may obviate the need for expensive and unnecessary evaluations. Discontinuation of the offending agent will usually achieve adequate blood pressure control. When use of a chemical agent which increases blood pressure is mandatory, anti-hypertensive therapy may facilitate continued use of this agent. We summarize the therapeutic agents or chemical substances that elevate blood pressure and their mechanisms of action.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bevacizumab; Blood pressure; Celecoxib; Drug-induced hypertension; Lapatinib; Medications; Prednisone Licorice acid; Rofecoxib; Sorafenib; Sunitinib; Tyrosine kinase inhibitors; Venlafaxine; chemicals; cyclosporin A

Mesh:

Year:  2015        PMID: 26096556     DOI: 10.1016/j.ejphar.2015.06.027

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

2.  Corticosteroid therapy and severity of vasogenic edema in posterior reversible encephalopathy syndrome.

Authors:  Neal S Parikh; Andrew D Schweitzer; Robert J Young; Ashley E Giambrone; John Lyo; Sasan Karimi; Anna Knobel; Ajay Gupta; Babak B Navi
Journal:  J Neurol Sci       Date:  2017-06-29       Impact factor: 3.181

3.  Use of Prescription Medications That Potentially Interfere With Blood Pressure Control in New-Onset Hypertension and Treatment-Resistant Hypertension.

Authors:  Andrew Y Hwang; Chintan V Dave; Steven M Smith
Journal:  Am J Hypertens       Date:  2018-11-13       Impact factor: 2.689

4.  Safety of Intravenous Methylprednisolone in Refractory and Severe Pediatric Uveitis.

Authors:  Hashem H Ghoraba; Wataru Matsumiya; Hassan Khojasteh; Amir Akhavanrezayat; Irmak Karaca; Christopher Or; Negin Yavari; Sherin Lajevardi; Jaclyn Hwang; Cigdem Yasar; Diana Do; Quan Dong Nguyen
Journal:  Clin Ophthalmol       Date:  2022-05-31

Review 5.  Common Substances That May Contribute to Resistant Hypertension, and Recommendations for Limiting Their Clinical Effects.

Authors:  Samuel J Jurca; William J Elliott
Journal:  Curr Hypertens Rep       Date:  2016-10       Impact factor: 5.369

Review 6.  Cardiovascular risk associated with high sodium-containing drugs: A systematic review.

Authors:  Germain Perrin; Virginie Korb-Savoldelli; Alexandre Karras; Nicolas Danchin; Pierre Durieux; Brigitte Sabatier
Journal:  PLoS One       Date:  2017-07-06       Impact factor: 3.240

Review 7.  Are cardiovascular comorbidities always associated with a worse prognosis in patients with lung cancer?

Authors:  Sabina Mędrek; Sebastian Szmit
Journal:  Front Cardiovasc Med       Date:  2022-09-23

Review 8.  Hypertension in older adults: Assessment, management, and challenges.

Authors:  Estefania Oliveros; Hena Patel; Stella Kyung; Setri Fugar; Alan Goldberg; Nidhi Madan; Kim A Williams
Journal:  Clin Cardiol       Date:  2019-12-11       Impact factor: 2.882

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.